News

Filter

Current filters:

Merck & CoZymeworks

Merck & Co in $187 million deal with Zymeworks to develop bi-specific antibody therapeutics; returns rights for PD drug to Addex

06-09-2011

Privately-held Canadian biotech firm Zymeworks and entered a research collaboration with US drug giant…

Addex PharmaBiotechnologyLicensingMerck & CoNeurologicalPharmaceuticalZymeworks

Back to top